{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:43:56Z","timestamp":1762865036843,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.rpth.2024.102363","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T23:43:28Z","timestamp":1709250208000},"page":"102363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Benitez-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Gidley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102363_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.14099","article-title":"Outcome measures in haemophilia: beyond ABR (annualized bleeding rate)","volume":"27","author":"Manco-Johnson","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/rth2.12331","article-title":"Clinical outcomes in hemophilia: towards development of a core set of standardized outcome measures for research","volume":"4","author":"Dover","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","article-title":"The cost of severe haemophilia in Europe: the CHESS study","volume":"12","author":"O'Hara","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2024.102363_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13561-018-0185-7","article-title":"The relationship between target joints and direct resource use in severe haemophilia","volume":"8","author":"O'Hara","year":"2018","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.rpth.2024.102363_bib5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/hae.14302","article-title":"Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A","volume":"27","author":"O'Hara","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib8","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/hae.13982","article-title":"Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027","volume":"26","author":"Reding","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score","volume":"63","author":"Feldman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rpth.2024.102363_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12690","article-title":"The Hemophilia Joint Health Score version 2.1 validation in adult patients study: a multicenter international study","volume":"6","author":"St-Louis","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2516.2006.01312.x","article-title":"Hemophilia joint health score reliability study","volume":"12","author":"Hilliard","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib12","first-page":"221","article-title":"Recent advances in the treatment of hemophilia: a review","volume":"15","author":"Marchesini","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.rpth.2024.102363_bib13","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2024.102363_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","article-title":"Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis","volume":"35","author":"Samuelson Bannow","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2024.102363_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A\u00a0novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"Stennicke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102363_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/rth2.12220","article-title":"Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A","volume":"3","author":"Chowdary","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102363_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12674","article-title":"Turoctocog alfa pegol (N8-GP) in severe hemophilia A: long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study","volume":"6","author":"Lentz","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/rth2.12212","article-title":"Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1","volume":"3","author":"Ribeiro","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102363_bib20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hae.14180","article-title":"Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: options for a shorter HJHS","volume":"26","author":"Kuijlaars","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/hae.14642","article-title":"Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study","volume":"28","author":"Kiialainen","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269215519879212","article-title":"Effect of manual therapy in patients with hemophilia and ankle arthropathy: a randomized clinical trial","volume":"34","author":"Donoso-\u00dabeda","year":"2020","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.rpth.2024.102363_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/hae.14016","article-title":"Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: a 6-year follow-up study","volume":"26","author":"Liu","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib25","first-page":"152","article-title":"Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study","volume":"18","author":"Zanon","year":"2020","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2024.102363_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/hae.13833","article-title":"Implementation and assessment of a self- and community-based rehabilitation programme in patients with haemophilia from C\u00f4te d\u2019Ivoire","volume":"25","author":"Lobet","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children","volume":"25","author":"Chozie","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/hae.13327","article-title":"Monitoring joint health in haemophilia: factors associated with deterioration","volume":"23","author":"Kuijlaars","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13353","article-title":"Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/08880018.2017.1313921","article-title":"Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A","volume":"34","author":"Zhao","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.rpth.2024.102363_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A\u00a0randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - a success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib32","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/hae.12090","article-title":"Functional limitations in Romanian children with haemophilia: further testing of psychometric properties of the Paediatric Haemophilia Activities List","volume":"19","author":"Groen","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/hae.14731","article-title":"Humanistic burden of problem joints for children and adults with haemophilia","volume":"29","author":"Burke","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2147\/PPA.S141392","article-title":"Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study","volume":"11","author":"Buckner","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2024.102363_bib35","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1111\/hae.12748","article-title":"Distress in patients with bleeding disorders: a single institutional cross-sectional study","volume":"21","author":"Barry","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2024.102363_bib37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib38","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102363_bib39","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102363_bib41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102363_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2516.2009.02178.x","article-title":"Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania","volume":"16","author":"Saulyte Trakymiene","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102363_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.rpth.2024.102363_bib44","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:28:39Z","timestamp":1762864119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2475037924000529"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102363","relation":{},"ISSN":["2475-0379"],"issn-type":[{"type":"print","value":"2475-0379"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102363"}}